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SARS-CoV-2: Current Therapeutics Human and Veterinary Medicine 
Abstract 
The Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, was first reported in 
Wuhan City, China, in December 2019. Health and environmental risk factors are crucial in this 
current pandemic, yet it is essential to note that even though individuals of all ages are susceptive 
to this virus, there are risk factors associated with developing the severe disease. It is also eminent 
to establish the human-animal interaction by tackling important past pathogenic viruses such as 
SARS-CoV and MERS-CoV and its zoonotic links. In need of a clinically established management 
for this outbreak, approved drugs' therapeutic interventions could help treat this disease, targeting 
its replication. The need to resolve the current pandemic of COVID-19 epitomizes the need for a 
different approach, drug repurposing. Characterization of artificial intelligence created by 
predicted models and structures could alleviate COVID-19; it has been used not only in the 
development of drugs but also in tackling screening, treatment, and contact tracing. This review 
presents pathogenesis, transmission, and the analysis of drug repositioning in both human and 
veterinary medicine of SARS-CoV-2 to delve into practical approaches to manage this disease.  
 Introduction  
Coronavirus (CoVs) belong to the order Nidovirales, including Coronaviridae, 
Roniviridae, and Arterivirdae families. Coronavirinae family is subdivided into four distinct 
genera: alpha, beta, gamma, and delta coronavirus, critical in both human and veterinary 
medicine. CoVs broadly infect vertebrates, including humans, birds, bats, snakes, mice, and other 
wild animals (Weiss, 2015). CoVs are highly transmissible and pathogenic positive-sense, single-
stranded RNA enveloped viruses, with a genome ranging from 26 to 32kb in length. The 5’terminal 
two-thirds of the genome contain open reading frames (ORFs), ORF1 and ORF2 encoding two 
distinct polyproteins pp1a, which cleaves into 11 proteins and pp1b, cleaving into 16 proteins. 
These proteins serve an essential function in the genome, allowing maintenance and virus 
replication. The structural proteins, namely spike (S), an envelope protein (E), membrane protein 
(M), and nucleocapsid (N), are located at the one-third 3′ terminal of the genome. (Malik,2020). 
N complex along with RNA genome provides a helical capsid configuration located inside the 
viral envelope. The trimers of S contribute to the virion corona or crown arrangement. 





specificity and receptor binding. Some CoVs have hemagglutinin-esterase (HE) protein in its 
virion, which forms a smaller spike to destroy specific receptors found on the host cells. 
Seven CoVs that infect humans have been identified; HCOV-229E and HCoV-NL63 
belonging to Alphacoronavirus, HCoV-OC43, and HCoV-HKU1, belong to Betacoronavirus, as 
well as SARS-CoV, MERS-CoV, and SARS-CoV-2. The pandemic of severe acute respiratory 
syndrome (SARS) in 2002–2003, the emergence of the Middle East respiratory syndrome (MERS) 
in 2012, and the emergence of a new coronavirus named severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), the causal agent of the coronavirus disease 2019 pandemic, are all 
examples of human infections leading to significant fatality caused by coronaviruses (Guarner, 
2020). The development of novel transmissible diseases epitomizes a liability to public health and 
a socio-economic impact on both humans and livestock. Analysis of the SARS-CoV2 (COVID-
19) sequence indicated that it shows 77.2% amino acid identity with SARS-CoV (SARS) with the 
non-structural proteins (nsp's) 7–10 showing between 97.1% to 98.8% identity (Wu, 2020). 
Consequently, it is imperative to understand SARS-CoV-2 to implement a functional management 
strategy, decreasing both transmission and morbidity. 
The subfamily of CoVs, as mentioned previously, comprises four genera alpha, beta, 
gamma, and delta coronavirus. The alpha and beta coronaviruses infect only mammals; gamma 
and delta coronaviruses infect birds, but some can also infect mammals (Decaro,2020). 
Coronaviruses like mouse hepatitis virus, rat sialodacryoadenitis CoVs, guinea pig CoVs, and 
rabbit CoVs are important viruses responsible for hepatitis, enteritis, and respiratory infections in 
lab animals.  
Among large animals, bovine coronaviruses (BoCVs) have zoonotic potential as being 
isolated from asymptomatic children and also found affecting several domestic and wild 
ruminants, in which calf diarrhea in neonates, bloody diarrhea in adult cattle and respiratory form 
of shipping fever in all age groups of cattle are universal implications (Tiwari, 2020). Feline CoVs 
also affect the respiratory and gastrointestinal tract, producing enteritis and infectious peritonitis 
(Tekes, 2016). There is an understanding that the virus has a zoonotic origin, yet much remains 
unknown. Bats are critical natural hosts of alphacoronaviruses and beta coronaviruses; the 
discovery of diverse bat CoVs closely related to SARS-CoV-2 suggests that bats are potential 
reservoirs of the virus (Hu, 2020). According to WHO, identifying the zoonotic source of the virus 





identifying intermediate hosts and their roles. As of November 2020, WHO has become vigilant 
of infected minks as a potential reservoir host. Not only that, but mutations have been reported; 
however, these variants are not yet understood, but it could result in a promising outcome. To date, 
six countries, namely Denmark, the Netherlands, Spain, Sweden, Italy, and the United States of 
America, have reported SARS-CoV-2 in farmed minks to the World Organization for Animal 
Health (WHO,2020). The continual human-animal interaction potentiates distress, particularly 
without the proper environmental biosecurity methods that could pose a potential threat, spreading 
the virus. 
SARS-CoV-2 pathogen was first reported in Wuhan City, China, in December 2019, after 
numerous patients presented pneumonia-like symptoms, including fever, dry cough, and shortness 
of breath followed by severe acute respiratory infections. In January 2020, it was announced that 
a new CoV had emerged named 2019-nCoV and later given the name of COVID-19 by the World 
Health Organization (WHO). The exponential spread of COVID-19 in January 2020 could be 
attributed mainly to Wuhan being the capital of China’s Hubei province. According to Guarner, 
Wuhan has over 11,000,000 inhabitants, and it is a central transportation hub, which increased 
person-to-person contact, adding to the possibility of exported cases to other locations.  The 
international spread of the virus accelerated by the end of February due to international travel. By 
March 2020, it was categorized as a pandemic. According to WHO, as of November 2020, over 
fifty million cases reported worldwide, and over ten million reported in the United States. Fatality 
obesity, high blood pressure as well as a weakened immune system.   
Due to the viruses' novel nature and unavailability of vaccine or specific therapy, it is vital 
to understand SARS-CoV-2 pathogenesis, transmission, and clinical signs. As this topic is fast-
changing, understanding the repurposing of drugs and human-animal interaction is fundamental to 
control this pandemic. This review presents pathogenesis and transmission and the analysis of 
current therapeutics in both human and veterinary medicine of SARS-CoV-2 to delve into practical 
approaches to manage this disease.  
SARS-CoV-2 Pathogenesis and Transmission  
Through accumulating data, the severity of Covid-19 is related to increase inflammatory 
cytokines and chemokines including (IL)-2, IL-7, IL-10, tumor necrosis factor (TNF), granulocyte 
colony-stimulating factor (G-CSF), monocyte chemoattractant protein-1 (MCP1; also known as 





chemokine ligand 10 (CXCL10), C-reactive protein, ferritin, and D-dimers in blood upon SARS-
CoV-2 infection (Tay, 2020). In most of those severe cases of coronavirus infection, the clinical 
expression is characterized not only by a fever, cough, and other constitutional symptoms but also 
by a clinical constellation including a cytokine storm, respiratory failure, and eventually death 
(Baden, 2020). 
SARS-CoV-2 spike binds to its receptor angiotensin-converting enzyme 2 (ACE2) through 
its receptor-binding domain (RBD) and is proteolytically activated by human proteases. 
(Shang,2020). COVID-19 can be divided into different phases corresponding to different disease 
clinical stages (Wu, 2020). The first stage is known as the asymptomatic stage; it encompasses the 
initial days of the virus. By numerous studies, asymptomatic infections make up a substantial 
percentage of confirmed COVID-19 cases. Asymptomatic infections are hidden and easily 
overlooked. However, their potential to spread the virus cannot be underestimated, as the viral load 
they carried and their ability to infect close contacts may be similar to those of symptomatic 
individuals. (Tan, 2020). Upper airway and conducting airway response correspond to the second 
stage. At this stage, the virus proliferates and continues down the respiratory tract; it also activates 
the innate immune response. The third and last stage is hypoxic, resulting in deprived oxygen 
supply leading to acute respiratory syndrome (ARDS). A systemic inflammatory response causes 
an unregulated immune response; a cytokine storm gives rise to the release of significant amounts 
of pro-inflammatory cytokines. This "intense attack" by the immune system promotes ARDS and 
multiple organ failure, leading to death in severe COVID-19 cases. 
The distribution of ACE2 receptors in different tissues could explain the difference in 
patient symptoms. SARS-CoV-2 binds to ACE2, the host cell receptor, which is found on the 
epithelium of other organs such as the intestine and endothelial cells in the kidney and blood 
vessels explain gastrointestinal symptoms and cardiovascular complications (Cevik 2020). The 
stipulation of olfactory dysfunction has become of attention as numerous patients presented a 
temporary loss of taste and smell, which can be attributed to damage in the olfactory epithelium. 
Much remains unknown, yet the clinical outcomes of SARS-CoV-2 are associated with underlying 
risks such as obesity, cardiovascular disease, and older age. Also, increased pro-inflammatory 
cytokines correlate with severe pneumonia and increased ground-glass opacities within the lungs 





Since declaring COVID-19 as a pandemic, it has been crucial to combat this disease. It has 
been established that this disease characterizes by person-to-person transmission, performance 
being both symptomatic and asymptomatic. Droplet transmission occurs by the direct spray of 
large droplets onto conjunctiva or mucous membranes of a susceptible host when an infected 
patient sneezes, talks, or coughs (Jayaweera, 2020). Infectious aerosols can pose an infection risk, 
especially in poorly ventilated or prolonged exposures to it. Current evidence on SARS-CoV-2 has 
limitations but strongly indicates aerosols as one of several routes of COVID-19 transmission. It 
should be noted that the equivalent evidence for contact and large droplet transmission is not 
available but has been an unproven assumption from the outset (Tang S, 2020).  
Health and environmental risk factors are crucial in this current pandemic, yet it is essential 
to note that even though individuals of all ages are susceptive to this virus, there are risk factors 
associated with developing the severe disease. Elderly individuals (aged > 60 years) and people 
with underlying chronic health conditions are more susceptible to severe disease (18.5%) as 
compared to children and younger healthy adults (6%) (Wang,2020) Recently, individuals with 
asymptomatic infection were also found to act as sources of infection to susceptible individuals. 
Both the asymptomatic and symptomatic patients secrete similar viral loads, which indicates that 
the transmission capacity of asymptomatic or minimally symptomatic patients is very high (Tan, 
2020). Also, incubation time is a crucial factor in infectious diseases, determined by the time 
elapsed between infection and appearance of the disease's first symptoms. Detailed 
epidemiological investigation and contact follow-up have shown that the virus's incubation period 
is typically between 3 and 7 days and no more than 14 days. During the incubation period, patients 
appear normal, with no symptoms, but can still spread the disease (Zhonghua, 2020).  
Drug Repurposing  
Drug development is a strenuous process that involves aiming at biotic targets involving 
biological processes. Analyses across all therapeutic areas indicate that new medicine's 
development, from target identification through marketing approval, takes over 12 years, and is 
often much more prolonged (DiMasi et al., 2017). Not only this, but the development process is 
costly and uncertain as many issues come into consideration; toxicity, lack of efficacy and safety, 
dosing ranges, and irreversible adverse effects. It usually costs an average of US$2.6 billion for 
approximately 17 years of development from molecule to market. Even so, only 2.01% of all drug 





The need to resolve the current pandemic of COVID-19 epitomizes the need for a different 
approach, drug repurposing. In this tactic, an established drug utilized can treat other diseases 
aiming at new targets, decreasing the developmental period. Usually, there are three steps before 
considering repositioning a drug: (1) the identification of candidate molecules for the given 
indication; (2) the theoretical assessment of the drug effect in preclinical models; and (3) the 
evaluation of safety efficacy in phase II clinical trials (Pushpakom et al., 2019 Economically it 
lowers the overall developmental costs by approximately $300 million (Low et al., 2020). This is 
of interest as commercially available drugs such as antivirals, protease inhibitors, antibacterials, 
antibiotics, IL-6 blockers, Jak inhibitors, and antimalarials are utilized as potential treatments for 
COVID-19. 
Different approaches within drug repositioning have become a significant complement in 
this pandemic. Computational Artificial Intelligence (AI) is defined as the mimicking of human 
intelligence demonstrated by machines, which entail reasoning, planning, learning, and perception 
to maximize the chances of achieving different goals under extreme load and urgencies like 
pandemics or diseases of unknown etiology (Low et al., 2020). Characterization of AI creates by 
predicted models and structures that could alleviate COVID-19. It has been used not only in the 
development of drugs but also in tackling screening, treatment, and contact tracing. Recent studies 
design an auxiliary tool to increase the accuracy of Covid-19 diagnosis with the new model 
Automatic COVID-19 detection based on a deep learning algorithm (Ozturk et al., 2020).  
AI and its drug-disease relationship could exponentially grow shortly as it allows for a 
faster, efficient, and low-cost alternative process. Challenges remain in developing these AI tools, 
such as data heterogeneity and low quality, insufficient data sharing by pharmaceutical companies, 
and the security and interpretability of the models. (Zhou et al.). In this review, we would explore 
the proposed repositioning of drugs targeting COVID-19 as these attempts are crucial in alleviating 
symptoms in the disease. As there is no current approved treatment or vaccination for COVID-19, 
drug recycling is urgent.  
Current Therapeutics 
As of November 2020, numerous vaccine trials are taking place, including nucleic-based, 
inactivated, and vector trial vaccines. These considerable efforts would still need to meet the 
primary essential criteria, safety.  Consequently, this review's primary aim is to evaluate current 





SARS-CoV-2 uses ACE 2 as the receptor and human proteases as entry activators; 
subsequently, it fuses the viral membrane with the cell membrane and achieves invasion (Hu, 
2020). According to Zirui, the virus principally targets airway epithelial cells and alveolar 
epithelial macrophages, all expressing ACE 2. The virus reduces ACE-2 in the lungs, and therefore 
the downregulation would lead to inflammasome activation promoting pyroptosis. This cell death 
resulting from inflammation would enable the damage-associated molecular patterns. This cascade 
would trigger pro-inflammatory cytokines, promoting further inflammation by the promotion of 
monocytes and macrophages. After entering the cell through clathrin-mediated endocytosis, the 
transmembrane protease serine 2 (TMPRSS2) cleaves to the S protein facilitating cell entry and 
fusion between the endosomal membrane and viral S2 sequence (Hoffmann et al., 2020). After 
fusion concluded, viral RNA is released to the infected host cell, promoting pathogenic responses 
and replication. In a first step, the open reading frame 1a/b (ORF1a/b) of the viral genome 
translates to produce the replicate proteins, after which the replicase-transcriptase complex DMVs 
assemble. In a second step, the replication complex reverse-transcribes the positive RNA genome 
into full-length negative-sense RNAs, which template the production of full-length daughter 
genomes and a subset of translation-focused mRNAs. These translation-dedicated transcripts 
contain a standard 5′ leader sequence cytosolically spliced to downstream genes, added by a 
discontinuous synthesis of minus sense subgenomic RNAs templating the positive RNA genome 
(Nitulescu, 2020).  
In need of a clinically established management for COVID-19, approved drugs' therapeutic 
interventions could help treat this disease, targeting its replication cycle. Not only this but 
understanding the animal-human interaction could expand current knowledge in prevention, 
control, animal CoVs evolution, as well as the adaption to humans due to zoonotic variations 
Human Medicine 
As continuously mentioned through this review, new data emergence and understanding of 
the virus increased the experimental drugs currently used. In the unavailability of treatment for 
COVID-19, market drugs are practical solutions in isolating a therapy for the disease. 
Consequently, lacking data on effectiveness and safety limits recommendation of treatment. 
Classification of drugs for the treatment of COVID-19 is generally classified; in this review, 
different drug classes are explored. Table 1 describes the drug classes, and the hypothesized 









Drugs Class Drug Suggested Mode of Action in SARS-CoV-2 
Antivirals 
Remdesivir 
Causes disintegration of NTP into replicating RNA by RdRp, 
preventing chain elongation after NTP plus three additional 
nucleosides, promoting premature RNA synthesis termination (Malin, 
2020). 
Favipiravir 
Selectively and potently inhibits the RNA-dependent RNA polymerase 
(RdRp).  
Ribavirin 
Creates random mutation that reduces the viability of the virus, as a 
consequence the viral response decreases as well as transmission 
Umifenvoir 
Blocks the virus-cell membrane fusion and virus-endosome fusion 
through incorporation into cell membranes and interference with the 
hydrogen bonding network of phospholipids (Villalain, 2010) 
Amantadine Block early stages of viral replication, inhibiting virion release in cell.  
Elbasvir 
Binds to RdRP, papain-like proteinase and helicases which are the 
main protein that SARS-CoV-2 replication is dependent on.  
Sofosbuvir Suppresses SARS-CoV-2 RdRp. 
Daclatasvir 
Binds to N terminus of nonstructural (NS5A) protein, inhibiting viral 
replication and assembly, whereas NS5B is an RNA-dependent RNA 
polymerase (RdRp) critical for RNA synthesis in HCV replication 




Lopinavir is a protease inhibitor that impedes viral replication. 
Ritonavir hinders CYP3A4,enlarging concentration of lopinavir 
(Horby, 2020). 
Nafamostat 
Prevents fusion of the envelope of the virus with host cell surface 
membrane (Jang and Rhee, 2020 
Nelfinavir 
Binds to the SARS-CoV-2 protease as well as inhibit cell fusion 





Obstruction of post-translation modification E proteins, as well as 
suppressed IL-6 and downregulated TNFR (Shende, 2020). 
Antibiotics 
Azithromycin Hinders viral reproduction and IL-6 assembly 
Doxycycline 
Inhibit the replication of single-stranded RNA viruses via inhibiting 
the viral serine protease (Rothan et. al, 2020). 
IL-6 Blockers 
Tocilizumab 
Selectively and competitively binds to soluble expressing the IL-6 
receptor and then blocking the signaling caused by IL- 6 (Sing et. al, 
2020)  
Lenzilumab 
Blocks the GM-CSF pathway reducing cytokine-induced inflammation 




Interact with SARS-CoV-2 and ACE 2 receptors could mitigate the 
cytokine storm by targeting critical cytokines 
Baricitinib Acts as a JAK inhibitor interfering with the inflammatory process. 
Corticosteroid 
Dexamethasone 
Activation of histone deacetylase may oppose the action of SARS-






Remdesivir and Favipiravir  
Drugs that have been tested or are still ongoing clinical trials for SARS-CoV-2 replication 
as subgenomic transcription include favipiravir (FPV) and remdesivir (RDV). FPV is an antiviral 
agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA 
viruses. (Furuta,2017). It does this by entering infected cells through endocytosis, which then 
targets RdRp by disrupting the nucleotide incorporation process during RNA replication. In Japan, 
FPV has been approved to manage pandemic influenza infection in 2014 (Agrawal, 2020).FPV is 
a nucleoside precursor which inhibits the broad range of influenza virus strains. However, it shows 
antiviral activity through its NTP form (converted into an active phosphoribosylated form, T-705 
RTP) via direct inhibition of the RDRP activity of influenza A virus polymerase, and it has also 
shown lethal mutations within the viral genome. (Singh et al.). According to Wang et al., a higher 
concentration of FPV is needed to inhibit SARS-COV-2 in Vero cells. Clinical trials are still 
ongoing, yet safe and efficient treatment regarding dosing and severity of illness is needed to 
determine FPV effectiveness. Along these lines, a drug tackling the immune response and viral 
replication inhibition would be promising to counteract the SARS-CoV-2 replication cycle. 
On October 22, 2020, FDA approved RDV for the treatment of COVID-19 requiring 
hospitalization. RDV is an antiviral nucleoside analog; it undergoes intracellular metabolic 
conversion to its active metabolite, nucleoside triphosphate (NTP). RDV causes disintegration of 
NTP into replicating RNA by RdRp, preventing chain elongation after NTP plus three additional 
nucleosides, promoting premature termination of RNA synthesis, which is needed for new 
generation virions (Malin, 2020). Its viral activities against SARS-CoV-2 have been shown in 
both in vitro and in vivo studies. Remdesivir has been used in several countries as an emergency 
drug for patients with COVID-19 (Frediansyah, 2020).  
Ribavirin 
Evaluating the role of ribavirin in treating the novel virus has also come into effect. The 
inability to tie zoonotic links influences the treatment currently studied. Ribavirin is a guanosine 
analog acting as a chain terminator by inhibiting RNA polymerase (Zhou et al., 2020). The earliest 
reported in vitro efficacy of five FDA‐approved drugs with activity against WIV04 has been 
reported; ribavirin, penciclovir, nitazoxanide, and nafamostat and chloroquine (Khalili, 2020). 





response decreases as well as transmission. Ribavirin has also shown immune response properties 
as an anticancer agent; as an enhanced polarization of Th1, regulatory cells would suppress the 
immune response, an indirect mechanism ( Li Z, 2016). Ribavirin is also very cheap compared to 
other drugs, allowing the medical product to be distributed readily to the public, challenging the 
pandemic. New clinical trials are currently in process, which will expand understanding of dosing, 
combination drugs, and its efficacy.  
Umifenvoir 
Umifenovir is a broad‐spectrum antiviral agent that could effectively inhibit the virus's 
fusion with host cells and is already licensed for prophylaxis and influenza treatment (Huang, 
2020). Its mechanism is to block the virus-cell membrane fusion and virus-endosome fusion by 
incorporating cell membranes and interference with the hydrogen bonding network of 
phospholipids (Villalain, 2010). This antiviral has been associated with a lower incidence of 
SARS-COV-2 infection but not hospitalization, yet much remains unknown; inconsistency in 
different studies concludes that randomized clinical trials should take place in order to confirm 
umifenovir effectiveness. 
Amantadine  
Amantadine has been utilized as an antiviral against the influenza A virus; the proposed 
mechanism is that the drug blocks the early stage of viral replication. When the viral particle enters 
the cell, an endosome is formed, with an acid pH of 5. The proton channel is formed by the M2 
protein, which carries protons into the virion's interior (Abreu,2020). The drug can pass through 
the endosome membrane, inhibit the virion release into the cell, and break the hydrogen bridges 
formed by Ala 30 and Gly 34 (Thomaston,2018). It could be expected that amantadine could lessen 
the disease's effects when the first symptoms occur. 
Elbasvir  
This drug is approved for the treatment of hepatitis C, and it has been predicted that it could 
bind to RdRP, papain-like proteinase, and helicases, which are the main protein that SARS-CoV-
2 replication depends on. In a recent study performed by Balasubramaniam et al., target-based 
computational analysis screening drugs that would target the virus's three main proteins were 
utilized. According to Balasubramaniam et al., several drugs are capable of a weak relationship 
with numerous viral proteins; elbasvir is characteristic in its probable high affinity for SARS-CoV-





Sofosbuvir and Daclatasvir  
Sofosbuvir is a pyrimidine nucleotide analog prodrug, has a hydrophobic masked 
phosphate group that enhances its ability to enter host cells (Jockusch et al., 2020). This antiviral 
has demonstrated evidence in vitro on viral RdRp and is hypothesized to suppress SARS-CoV-2 
RdRp. Daclatasvir, as an antiviral, binds to the N terminus of nonstructural (NS5A) protein, 
inhibiting viral replication and assembly, whereas NS5B is an RNA-dependent RNA polymerase 
(RdRp) critical for RNA synthesis in HCV replication (Kumar, 2020). These direct-acting 
antivirals have shown in an in vitro (albeit non–peer-reviewed) study the inhibition of SARS-CoV-
2 virus particles by daclatasvir in Vero cells, hepatoma cell line, and type II pneumocytes (Kumar, 
2020). These drug's low-cost expense and treatment outcomes reported promising results in the 
near future, yet more extensive studies are needed to assess effectiveness.  
Protease Inhibitors  
Lopinavir/Ritonavir  
Protease inhibitors employ competitive binding to the site of viral enzymes breaking down 
proteins and peptides. Lopinavir/ritonavir (LPV/r) combination has been widely recognized and 
used to inhibit the HIV protease enzyme. It hypothesized that the 3CL-pro-inhibiting activity of 
LPV/r influences anti-CoV effects (Zumla, 2016). As of November 2020, drugs counteracting the 
attachment to the virus' polymerase, LPV/r, have been discontinued. According to WHO, these 
drugs do not provide substantial evidence of a reduction in hospitalized patients' mortality. 
Additionally, allocation to lopinavir-ritonavir was not associated with reductions in hospital stay 
duration or the risk of being ventilated or dying for those not on ventilation at baseline. These 
results were consistent across subgroups of age, sex, ethnicity, duration of symptoms before 
randomization, amount of respiratory support at randomization, and baseline predicted risk of 
death at randomization (Horby, 2020). 
Nafamostat 
This drug has been utilized for the treatment of pancreatitis and disseminated intravascular 
coagulation in Japan. This drug shows the activity as an anticoagulant, anti-inflammatory, and 
antiviral activities in COVID-19. Nafamostat prevents the fusion of the virus's envelope with the 
host cell surface membrane (Jang and Rhee, 2020). In a study of 3 elderly patients with progressive 
pneumonia and at high risk based on age, Nafamostat was utilized, improving clinical status. 





immune system such as the complement cascade, hindering DIC, impeding virus invasion by 
hindering virus fusion on the cell membrane. Thus, it was observed that the antiviral drug improved 
clinical outcomes; a more significant sample size is essential for a better evaluation of this 
treatment. 
Nelfinavir            
        Acts as an HIV-1 protease inhibitor, also it produces numerous influences on cellular 
processes as stimulation of apoptosis and necrosis. Molecular docking studies predict that 
nelfinavir binds to the SARS-CoV-2 protease and inhibits cell fusion caused by the SARS-CoV-2 
S glycoprotein (Ianeyski et al., 2020). Preliminary experiments indicate that S‐n and S‐o may be 
cleaved in Vero cells in the presence of nelfinavir, although it is not currently known whether this 
cleavage occurs efficiently (Musarrat et al., 2020). Nelfinavir also studied in a combination of 
amodiaquine- host-directed- which has a similar action mechanism to chloroquine. It was noted to 
better efficacy and decreased toxicity for the treatment of SARS-CoV-2 and perhaps other viral 
infections (Ianeyski et al., 2020). This combination could have a crucial function in COVID-19 
and should be furthered looked into.    
Antimalarials  
 
Chloroquine and Hydroxychloroquine 
 
Chloroquine and its analog hydroxychloroquine have long been used worldwide as 
frontline drugs for treating and human prophylaxis of malaria (Tripathy et al., 2020). Inhibition of 
SARS-CoV-2 entry through the endocytic pathway or fusion with the host cell would be attributed 
to antimalarials. Chloroquine, as well as hydroxychloroquine, were proposed as a therapy for 
COVID-19 as it obstructed post-translation modification E proteins, as well as suppressed IL-6 
and downregulated TNFR (Shende, 2020). Hydroxychloroquine should be cautiously used in 
patients with known hepatic or renal dysfunction. The co-administered drugs with 
hydroxychloroquine excreted via liver/kidney may interact with hydroxychloroquine and 
modulate its pharmacokinetics and toxicity (Singh et al., 2020). According to Agstam et al., 
hydroxychloroquine and chloroquine are associated with a high prevalence of QT prolongation. 
Subsequently, rigorous monitoring is advised. A protocol designed to study Remdesivir, 
Hydroxychloroquine, Lopinavir, and Interferon- 1a and its effect on mortality was assessed in 





including numerous hospitals in different countries. From March 22 to October 4, 2020, 11,330 
patients were entered from 405 hospitals in 30 countries in all 6 WHO regions (WHO,2020). 
According to WHO, on July 4, 2020, the international trial discontinued the hydroxychloroquine 
and lopinavir/ritonavir group receiving the intervention of these drugs as it showed no reduction 
in the mortality of COVID-19 in comparison to the standard of care. The overall findings also 
tackled hydroxychloroquine's cardiotoxicity, but there was no indication of excess mortality due 




This drug is a macrolide antibiotic used primarily to treat respiratory infections. 
Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory 
inflammatory diseases for this purpose (McMullan and Mostaghim, 2015). In the COALITION II 
study, the efficacy of hydroxychloroquine and azithromycin was assessed. According to 
Oldenburg, azithromycin showed no benefit on clinical outcomes, including clinical status or 
mortality, when added to the standard of care regimen. The results emphasized the findings from 
COALITION I, yet azithromycin's role should be evaluated earlier in the disease as it is the most 
commonly prescribed outpatient therapy for COVID-19 (Oldenburg, 2020). Thorough analyses of 
this antibiotic and its use for the current pandemic is needed for accurate prescription rationale. 
Doxycycline 
Through literature identification, doxycycline has been reached to treat the SARS-CoV-2 
virus. As demonstrated with the dengue virus in vitro, doxycycline may also inhibit the replication 
of single-stranded RNA viruses via inhibiting the viral serine protease (Rothan et al., 2020). 
Tetracyclines can also induce activation of Protein Kinase C apoptosis of mast cells, thus 
decreasing levels of circulating agents (Sandler et al., 2005). These conclusions facilitate the 
conclusions that this drug could aid in the cytokine storm prompted by the virus inhibiting Mpro. 
Interleukin-6 (IL-6) Blockers 
Tocilizumab  
This drug is mostly used for rheumatoid arthritis and currently demonstrate potential 
treatment for the fatal patient with COVID-19, improving lung tissue inflammation. Tocilizumab 
selectively and competitively binds to soluble expressing the IL-6 receptor (IL-6) and then 





associated with rapid recovery for hyper inflammation in the patient experiencing COVID-19 as 
an adverse effect such as liver toxicity has been explored. As a result, efficacy needs to be assessed 
to adjust dosing as this drug is under review. Thus, it could suggest a good alternative for the 
patient in a terminal state (Singh et al., 2020). 
Lenzilumab  
           Lenzilumab, a recombinant monoclonal antibody against granulocyte-macrophage colony-
stimulating factor, has been shown to reduce several inflammatory mediators, making it another 
suggested treatment for cytokine-release syndrome, CRS (Melody et al., 2020). In the current 
ACTIV-5 Big Effect Trial comprising over 40 U.S sites to accelerate the innovation for COVID-
19, investigating lenzilumab in a combination of remdesivir against remdesivir and lenzilumab 
placebo. The extensive trial's purpose is to evaluate clinical efficacy regarding different 
therapeutics at day eight and the amount of time it takes for a patient to recover from the disease. 
The experimental arm intervention is 200-mg intravenous (IV) remdesivir loading dose on Day 1, 
followed by a 100-mg once-daily IV maintenance dose up to a 10-day full course while 
hospitalized and 600-mg IV lenzilumab infusion every 8 hours starting on Day 1 for a total of 3 
doses. N=100 (NIH,2020). As the recognition of this drug has become apparent as an 
immunomodulator and remdesvir, thorough testing is needed to determine its efficacy. 
Kinase Inhibitors  
Ruxolitinib  
This drug is a JAK1/JAK2 inhibitor showing anti-inflammatory properties. It has been 
approved for the use of myelofibrosis and polycythemia vera (Vannucchi et al. t, 2015). 
Ruxolitinib displays valuable proficiency in severe respiratory expression. It is also associated 
with coagulopathy regarding COVID-19. The triggering of the innate immune response needs to 
be further studied regarding hypercoagulability with complement-mediated microthrombotic 
expressions (Connors and Levy, 2020). Ruxolitinib's interaction with the virus and ACE 2 
receptors could mitigate the cytokine storm by targeting critical cytokines. In a study, seven 
cytokines markedly decreased in the patient receiving the drug: IL-6, nerve growth factor β, IL-
12(p40), inhibitory migration factor, MIP-1α, MIP-1β, and VEGF in comparison to the control 
group (Cao et al., 2020) This finding could instigate further studies to incorporate Ruxolitinib in a 







On November 19, 2020, the FDA approved the emergency use of baricitinib combined 
with remdesivir in the hospitalized patient needing oxygen. According to the FDA, patients using 
the combination of these drugs had a reduction in recovery compared to patients receiving placebo 
in the Adaptive COVID-19 Treatment Trial 2(ACTT-2). Baricitinib acts as a JAK inhibitor 
interfering with the inflammatory process. Its therapeutic dose of 2mg or 4mg once daily is enough 
to inhibit AP2-associated protein kinase 1 (AAK1), a regulator of the endocytosis process 




This drug is a glucocorticoid with anti-inflammatory and immunosuppressive actions. On 
SARS-CoV-2, nsp5 inhibits HDAC2 transport into the nucleus, impeding how it mediates 
inflammation and cytokine response. Therefore, dexamethasone's activation of histone deacetylase 
may oppose the action of SARS-CoV-2 (Ortolani,2020). Due to the RECOVERY trial, it was 
concluded that a controlled dose of dexamethasone, 6 mg daily for ten days, lowered mortality in 
hospitalized patients with COVID-19 and respiratory failure who required therapy with 
supplemental oxygen or mechanical ventilation (Horby et al., 2020). The use of corticosteroids is 
inconclusive but based on the literature, it could potentially decrease the mortality rate in acute 
patients. 
Numerous drugs are still under investigation; the understanding of this virus is still 
relatively new. The drug reviewed are part of the current, proposed, or discontinued therapies for 
the virus. Revising the drug's efficacy through different randomized, double-blind, and controlled 
trials are of utmost importance to understand and target COVID-19. At this time, further research 
is needed to tackle this global health threat.  Figure 1 depicts some of the current therapies utilized 







Fig 1: Mechanism of action of major repurposing agents against COVID-19. Jamshaid, H., 
Zahid, F., Din, I.u. et al. Diagnostic and Treatment Strategies for COVID-19. AAPS 
PharmSciTech 21, 222 (2020). https://doi.org/10.1208/s12249-020-01756-3  
 
Veterinary Medicine 
Zoonotic links are vital to identify and understand its wide host range, especially with 
CoVs. The initial assumption with SARS-CoV-2 and its relation to animal source was from Wuhan 
Seafood Market. In Wuhan, Hubei Province, China, restaurants are famous for offering various 
small and large domestic animals, wild animals, and live animals, including poultry, rabbits, bats, 
snakes, pangolins, turtles, hedgehogs, badgers, and marmots for human consumption (Tiwari, 
2020). According to Li et al., bats appear to be the natural reservoir or source of origin for SARS-
CoV-2; the intermediate host is still in question. Amongst CoVs, recent zoonotic ones such as 
SARS-CoV, MERS-CoV, and SARS-CoV-2 gained higher importance due to the severity of 
disease in humans and their global spread (Rothan, 2020). In the current COVID-19 pandemic, 
laboratory findings confirmed that SARS-CoV-2 is also 96% identical to the bat CoV at the 
genomic level, and hence bats may be the primary source of this zoonotic spillover (Andersen, 
2020).  
Strains have been isolated from pangolins reporting that the E, M, N, and S genes encoding 





98.6, 97.8, and 90.7% amino acid identity, respectively (Xiao et al., 2020). This finding could aid 
in further studies focusing on pangolins as intermediate hosts, yet at this point, it is uncertain. As 
mentioned earlier, minks have also brought attention as a potential intermediate host after 
outbreaks in the Netherlands' farms. The most probable explanation for the widespread infection 
on the mink farms is the transmission of the virus by humans and subsequent transmission among 
the minks. Ferrets, which are near related to minks, were also able to transmit the virus to other 
ferrets under experimental conditions; transmission was observed under direct and indirect contact 
(Oreshkova, 2020).  
The human interaction with their pets could also possess a risk. Among the investigated 
animals, cats have the highest proportion of ACE2 and TMPRSS2 co-expressed cells regarded as 
SARS-CoV-2 target cells (Shi et al. 2020). Effective drugs have been evaluated in feline 
coronavirus inhibiting the main protease of SARS-CoV-2 Mpro. It autocleaves itself between nsp4 
and nsp6 before processing the overlapping polyproteins pp1a and pp1ab at 11 cleavage sites 
(Muramatsu,2013). Mpro enzyme has crucial influence for SARS-CoV-2. In a recent study by 
Vuong et al., the prodrug GC376 and GC373 were examined to inhibit SARS-CoV-2. These drugs 
have been tested in feline infectious peritonitis (FIP), effectively inhibiting Mpro of feline 
coronavirus. Both GC373 and GC376 inhibit the SARS-CoV Mpro and the SARS-CoV-2 Mpro 
in vitro at nanomolar concentrations (Vuong et al., 2020). These findings denote that these drugs 
should be contemplated for treatment of COVID-19 in human trials.  
Further studies of SARS-CoV-2 infection in diverse animal species are needed to 
understand the influences of transmission in different species. As of now, identification of the 
reservoir host is fundamental for the advancement of zoonotic links. As in minks' case, we learned 
human-animal reverse spread, which could lead to new antigenic types of SARS-CoV-2. Thus, the 
critical framework for future studies was initiated by Mpro and its inhibiting capacities by GC373 
and GC376. 
Conclusion  
COVID-19 has spread rapidly in the past year, causing concern, uncertainty, and fear as it 
became a public health crisis. In this literature review, the repurposing of drugs was a tackle, and 
the identification of divergences still exists as this disease is relatively new. Interdisciplinary 
contributions in human and veterinary medicine should be promoted, and in so, the prevention of 





would enhance early detection, treatment as well as the development of new drugs by offering 
updated information at a faster rate. Numerous drugs are being approved, refuted, and reviewed to 
enable strategic interventions. As there is no approved drug to treat this disease, it is imperative to 
follow the general public guidelines, wear a mask, practice social distancing, and practice good 
hygiene. In the future, drugs reviewed and a combination of old or new drugs could potentially 
resolve this pandemic. Understanding basic pathogenesis driven by computational analysis could 
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